Information Provided By: 
Fly News Breaks for November 15, 2018
ONCE, PRQR
Nov 15, 2018 | 07:52 EDT
Citi analyst Yigal Nochomovitz started ProQR Therapeutics (PRQR) with a Buy rating and $32 price target. The company's lead program for Leber congenital amaurosis 10, a severe eye disease leading to childhood blindness, has achieved proof-of-concept, Nochomovitz tells investors in a research note. The data reflect a degree of visual benefit "arguably better" than what Spark Therapeutics' (ONCE) Luxturna showed in the related disease LCA2, says the analyst.
News For PRQR;ONCE From the Last 2 Days
There are no results for your query PRQR;ONCE
